Indian syringes & needle manufacturers seek price cap & inclusion in NLEM

New Delhi: While pharma industry has been usually shying away from regulations, however, in an unusual move the syringes and needle manufacturers have written to Chairman of NLEM (National List of Essential Medicine) Committee  to include all types of syringes & needles in NLEM (National List of Essential Medicines), at the earliest so that they could come under Price capping of MRP.

In a letter to Prof Balram Bhargava, Secretary, Department of Health Research and Director General, Indian Council of Medical Research, AISNMA raised serious concerns  regarding the various news reports of exorbitant price being charged to the hapless Patients and the pleas of Patient groups to address this exploitation.

Indian syringes and needle manufacturers have urged the government to impose a price cap to stop the exploitation of patients by hospitals. The price limit on needle and syringe would curb unethical practices in the medical field and overcharge of these products by hospitals.

“We want a level-playing field. Hospitals need not sell at the MRP and are free to sell under the Max Retail Price but Doctors have been blaming us (manufacturers) for labelling products with high MRP. With Price Caps or Cap on Trade Margins ,our endeavour is to make the hospitals focus on making the procurement decision on the quality of the Medical Devices and their buying price for cost minimization rather than current skewed market where hospitals focus on Margins to be made on Higher MRPs and tend to seek profit maximisation . This has taken away the motivation of hospitals to be Cost competitive and patients feel exploited leading to a Trust deficit” said Mr Rajiv Nath, President, All India Syringes and Needles Manufacturers Association (AiSNMA).

“To stop patient exploitation being carried out by some manufacturers and importers through unethical marketing, it is of utmost importance for the Govt. to include all types of syringes & needles in NLEM (National List of Essential Medicines). Though, medical devices are engineering products, they are being regulated as drugs under the Drugs & Cosmetics Act, 1940 and Syringes and Needles are possibly more important than implants, as being used on almost all hospitalized Patients. Syringes and needles are among the most commonly used device which account for huge bills. There is also a higher risk of reuse and misuse of syringes and needles leading to burden of disease when Syringes & Needles carry excessively high MRP and become unaffordable.” said Mr Vimal Khemka, Secretary of AiSNMA.

“Since the Product range is very large due to different variety and sizes, instead of an absolute Price Cap which may be impractical, we, at AISNMA, collectively seek capping of Trade Margin to Maximum 75% on Ex-Factory prices for domestic manufacturer and on CIF value (landed cost) for Overseas Manufacturers on all types of syringes and needles, as this is more transparent and traceable in GST regime, being the 1^st point of imposition of GST,” stated Mr Nath further.

As per AiSNMA, this  will give a level playing field for all the domestic manufacturers as well as with overseas manufacturers, and will cut down, more than 1000% mark up being currently charged at present, by some of the manufacturers/importers and having a huge price disparity of 3 times the MRP for the same products and specifications.

“This landmark initiative if carried forward speedily by NLEM committee will help benefit the common people at large and simultaneously boost domestic manufacturing, reduce motivation to Reuse Syringes, increase the market size and correct market dynamics to a cost based competitive procurement by Hospitals. We urge the Government for carrying forward the process from NLEM listing to being declared a Scheduled Formulation to Price capping via Trade Margin Capping.This will ensure towards making these essential products available across the country at affordable prices,” added Mr Nath.